Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
Jack D. Scott(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael W. Miller(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sue‐Ing Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gautam Agnihotri(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ravi P. Nargund(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert E. Drolet(United States Military Academy), Marco A. S. Baptista(Merck & Co., Inc., Rahway, NJ, USA (United States)), Duane E. DeMong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sarah W. Li, Mark W. Embrey(United States Military Academy), Ronald K. Chang(United States Military Academy), Eric M. Parker(University of New Hampshire), Marc Poirier(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alan Hruza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Walsh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhicai Shi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Matthew Kennedy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. Sanders(United States Military Academy), Megan K. Macala(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark T. Bilodeau(United States Military Academy), Reshma Kuvelkar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sylvie M. Sur(United States Military Academy), Christian Mirescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Morrow(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan Kern(LIGO Scientific Collaboration), Zhizhang Yin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Heather E. Tiscia(United States Military Academy), Joel M. Harris(Merck & Co., Inc., Rahway, NJ, USA (United States)), John J. Renger(United States Military Academy), Matthew Fell(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas J. Greshock(University of Michigan), Kallol Basu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoping Zhang(Tongji University), Hong Liu(Chinese Academy of Sciences), Xiaoping Zhou, Li Xiao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yinghui Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xing Dai(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hong Mei(Merck & Co., Inc., Rahway, NJ, USA (United States)), Honglu Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), John Columbus(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. McCauley(Fox Chase Cancer Center), Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhiyong Hu(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 147
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336
Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents
|Proceedings of the National Academy of Sciences|1999|326
Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells.
|Journal of Biological Chemistry|1991|283